Introduction
Radiolabeled monoclonal antibodies, by virtue of their specificity for tumor-associated antigens, hold great promise as tumor imaging and therapeutic agents (Mach et al., 1981) . These agents have yet to fulfill this promise in part due to their commonly not achieving high tumor/non-tumor ratios following i.v. administation (Strauss et al., 1985) . While the use of antibody fragments, particularly the F(ab'), fragment, has been helpful in this regard, other approaches such as intralymphatic or regional delivery also hold forth promise (Wahl et al., 1983; Weinstein et al., 1982; Epenetos et af., 1982) . One such regional approach, the i.p. delivery route, has pharmacologic appeal in that high regional delivery advantages for chemotherapeutic agents and monoclonal antibodies can be seen following i.p. administration (Dedrick et al., 1978; Wahl et al., 1985a) . These higher levels of antibody in the peritoneal cavity, as compared to the blood, may be useful in treating or diagnosing tumor foci in the peritoneal cavity.
Despite the rational pharmacologic basis for this expectation of enhanced i.p. delivery to i.p. tumors, only limited quantitative preliminary studies of this approach to tumor delivery have been reported. Our preliminary studies in an animal system did not show advantages in terms of antibody delivery to large i.p. tumors (as compared to extraperitoneal tumors in the same animals) following i.p. antibody delivery when assessed several days post-antibody injection (Wahl and Piko, 1985d) . Other preliminary studies in man do suggest improved antibody delivery to small i-p. tumor foci following i.p. monoclonal antibody delivery as compared to i.v. monoclonal antibody delivery (Colcher et al., 1986) . Recently, we have shown that the i.p. delivery route is superior to the i.v. route in the treatment of i.p. colon cancer using radiolabeled antibodies (Wahl et al., 1987) . Thus, i.p. antibody is RICIURD L. WAHL and SUSAN FISHER superior to i.v. delivery for i.p. tumor therapy. The lack of enhanced tumor delivery in large tumors, when assessed several days post-injection, may be related to the large size of i.p. tumors, but it is also possible that because the pharmacologic i.p. delivery advantage is somewhat short-lived, mainly in the first 24 h after the administration of i.p. antibody (Wahl et al., 1985a) , that the high initial delivery advantage to i.p. tumors may be masked by later high systemic antibody levels and resultant delivery to non-target tissues by antibody that has entered the bloodstream from the peritoneal cavity.
A potential means to increase the regional delivery advantage following i.p. antibody delivery would be to increase the rate of systemic clearance of antibody without (ideally) accelerating the rate of decline in i.p. antibody levels. One approach capable of accelerating systemic clearance is the use of liposomally entrapped second (anti-mouse) antibody (Begent et al., 1982) . A somewhat simpler approach designed to accelerate blood-pool antibody clearance is the use of a polycolonal anti-mouse antibody to accelerate the clearance of mouse monoclonal antibody from the circulation. This approach has been successfully used by Sharkey and co-workers to improve tumor/background ratios following the intravascular administration of radiolabeled polyclonal anti-CEA antibodies to hamsters with CEA-producing colon tumors (Sharkey et al., 1985) . This approach with unlabeled polyclonal antibodies (in contrast to efforts with unlabeled monoclonal anti-mouse antibodies) appears to achieve clearance of blood pool radiolabeled anti-tumor antibody through the formation of immune complexes which are then deiodinated by the liver (Sharkey et al., 1985; Wahl et al., 1985b) .
In this study, we investigated in normal rats, the ability of polyclonal anti-mouse antibodies administered intravenously to accelerate the blood clearance of an iodinated monoclonal antibody administered intraperitoneally. We also measured the i.v. unlabeled polyclonal anti-mouse effect on peritoneal fluid radioantibody levels following i.p. administration of the radiolabeled antibody. The goal of this work is to determine if the regional delivery advantage of antibodies administered intraperitoneally could be increased in efforts to better diagnose and treat i.p. neoplasms using radiolabeled monoclonals.
Methods
UPC-10 is an IgG2aK monoclonal antibody purchased in purified form from Litton Bionetics and labeled with 125I by the iodogen method (Markwell, 1982) . Labeling was performed by mixing 100 pg of UPC-10 with 1 mCi of 12sI (NEN) in a vial coated with 2Opg of iodogen. Yields of 60-80% proteinbound iodine were typical. The lack of free iodine in the final preparation was confirmed by silica gel thin layer chromatography using a 50% ethanol/50% ethyl acetate buffer system (Wahl et al., 1985~) .
Polyclonal affinity purified goat anti-mouse antibody was purchased from Cappel (Malvem, Penn.).
Adult, approximately 200 g female SpragueDawley rats, were sedated with pentobarbital (i.p. 40-70mg/kg) and while under sedation were immobilized in the supine position. A small incision was made in the skin of the abdomen, and under direct visualization, 20 cm' warmed pH 7.2 phosphate buffered saline, containing 10-50 PCi of "'1 UPC-10 (2-7pg), was instilled via a 25 gauge needle into the peritoneal cavity. Animals were kept sedated for the next approximately 10 h, using repeated small doses of pentobarbital.
During this time, sequential blood and peritoneal fluid samples were obtained for radioactivity and weight determination. Blood was removed from the tail vein, while 50-100 PL volumes of the peritoneal fluid were removed using a syringe fitted with a 28 gauge needle, under direct visualization.
In one series of experiments, 6 h following i.p. 12sI UPC-IO injection the sedated rats (n = 14) were injected with either normal saline intravenously (25OpL) or with 250 pg (25OpL) of the affinity purified goat anti-mouse IgG intravenously. Animals continued to have blood samples obtained (in these animals the peritoneal fluid was not reliably obtained beyond 10 h post-injection due to absorption) following their regaining consciousness 10 h post UPC-10 injection, and they were subsequently sacrificed with tissue radioactivity levels and sample weights determined 24 h following 1251 UPC-IO injection using standard tissue handling techniques (Wahl et al., 1984) . In another set of experiments, rats received the lz51 UPC-10 intraperitoneally, but received a 250 pg of affinity-purified goat antimouse antibody dose intravenously 1.5 h post-intraperitoneal radioantibody injection. Percent kg dose/g was determined for each time point (% kg dose/g is % injected dose/g times the animals weight in kg). Radioactive decay was corrected for, and areas under the blood and peritoneal fluid curves were determined in each animal by determining AUC on graphs of individual animal's blood and i.p. fluid radioactivity levels in order to calculate the regional delivery advantage (Rd = AUC IP/AUC blood) (Dedrick et al., 1978; Wahl et al., 1985a) . Differences between tissue levels of radioantibody were analyzed using the unpaired Student t-test or analysis of variance.
Results
The blood levels and peritoneal fluid levels of intact 125I UPC-10 given by the i.p. route are shown in Fig. 1 . Note that in the saline-treated control group blood levels maximize at about 15 h into the study, and that peritoneal fluid levels change little following injection of the antibody intraperitoneally. Peritoneal fluid is generally totally resorbed (so that sampling is not possible) by 10-15 h into the study, Figure 1 also demonstrates that following the administration of the goat anti-mouse antibody intravenously at 6 h post-intraperitoneal antibody administration there is a rapid and sustained drop in blood levels of '25I UPC-IO. Although there is a large difference in blood levels between the saline and anti-mouse groups, this is in contrast to the lack of change in peritoneal fluid levels between the saline and anti-mouse groups. This difference in blood levels is highly significant between the saline and anti-mouse antibody groups (P < 0.01) at all times evaluated post the anti-mouse or saline administration as is the enhancement in Rd at 10.08 f 1.29 vs 6.20 + 1.09 measured from 0 to 10 h post-injection (P < 0.025). The enhanced Rd was due to this 6-9 h effect. There was no significant difference between 0 and 6 h Rd for the saline and the anti-mouse given at 6 h group. The Rd measured between 6 and 9 h was 3.79 f 0.49 for the saline group, but increased to 6.97 f 0.882 for the anti-mouse group (P < 0.0005).
The tissue distribution of I251 UPC-10 activity at sacrifice (Fig. 2) shows that there is a significant drop in activity in nearly all tissues in the animals given polyclonal goat antimouse antibody. The two exceptions were the spleen (where no drop in activity was giving the polyclonal anti-mouse antibody at 1.5 or of unlabeled antibody would be essential in each 6 h following i.p. UPC-10 injection (10.90 vs 10.08). system studied.
Discussion
Antibody binding kinetic considerations indicate that high local concentrations of antibody bathing tumor cells should produce better tumor uptake than if lower concentrations of antibody are present (Renacerraf and Unanue, 1979) . Increasing data supports the i.p. antibody route's superiority over the i.v. in localizing and treating i.p. tumors. Our study shows that the administration of polyclonal anti-mouse antibodies intravenously results in a significantly prolonged drop in blood radioantibody levels, and thus normal tissue levels of radioactivity, without significantly altering i.p. fluid radioantibody levels. This higher antibody concentration in the peritoneal cavity relative to blood levels (regional delivery advantage) should produce better tumor/ non-target uptake for small i.p. tumor foci than would be present if no incremental increase in i.p. concentration was present. Only two normal tissues did not have diminished uptake with polyclonal anti-mouse treatment vs saline treatment: splenic radioantibody levels did not drop with unlabeled anti-mouse treatment relative to spleens in salinetreated animals. Presumedly the spleen takes up immune complexes formed by cold anti-mouse antibody and labeled UPC-IO, as does the liver, but the spleen cannot deiodinate them as effectively, resulting in no drop in activity. The thyroid, which was deliberately left unblocked in these studies accumulated significantly more 123 activity/g in those animals treated with cold anti-mouse antibody than did the saline group. This is most compatible with increased availability of free '25I to the thyroid due to dehalogenation occurring more rapidly in the cold antibody treated rats.
In conclusion, our study demonstrates that while a major regional delivery advantage exists for an intact murine monoclonal IgG antibody given intraperitoneally, this delivery advantage can be significantly enhanced by the systemic administration of polyclonal anti-mouse antibodies, allowing for the rapid clearance of '25I UPC-10 from the blood after it diffuses there from the peritoneal cavity. This approach of accelerated systemic clearance provides a pharmacokinetic rationale for improving regional delivery to any body cavity and may be particularly useful in the diagnosis and treatment of i.p. carcinomas such as ovarian and colon cancers.
